April 7, 2022: Heidelberg Pharma AG

Heidelberg Pharma to Present New Data on its Proprietary ATAC® Technology Platform at the AACR Annual Meeting 2022

Heidelberg Pharma AG announced today that it will present preclinical data on its proprietary Amanitin-based ATAC® technology at the American Association for Cancer Research (AACR) 2022 Annual Meeting. The meeting will take place in New Orleans, Louisiana, USA, from 8th – 13th April 2022.

Details of the poster presentation:
Amatoxin-based antibody-drug conjugates induce immunogenic cell death and improve the anti-tumor efficacy of immune checkpoint inhibitors in humanized mouse models

Please read the whole article here

Heidelberg Pharma AG, News 2022

March 30, 2022: AC Immune SA

AC Immune KOL Webinar on First Clinical Proof of Concept for Alpha-synuclein Diagnostic Shows Breakthrough Potential for Neurodegenerative diseases

a-syn PET tracer, ACI-12589, clinically validated in MSA, potentially enables accelerated development of targeted therapeutics and additional a-syn diagnostics

Another first for validated Morphomer® discovery technology platform in developing small molecules able to selectively target pathological human proteins

AC Immune pipeline includes a-syn diagnostic and multiple a-syn therapeutic candidates

AC Immune on track to deliver seven clinical data readouts in 2022

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, hosted leading research scientist and key opinion leader Dr. Oskar Hansson for a webinar focused on a-synuclein as a diagnostic and therapeutic target in neurodegenerative diseases. AC Immune and Dr Hansson reported at the recent AD/PD™ conference, data showing that AC Immune’s wholly owned a-syn PET tracer ACI-12589 was the first-ever radiotracer to distinguish multiple system atrophy (MSA) from other a-synucleinopathies, i.e. Parkinson’s disease (PD) and Lewy body dementia (LBD), and healthy volunteers.

Please read the whole article here

AC Immune SA, News 2022

March 30, 2022: CureVac AG

CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV

Phase 1 dose-escalation study started at clinical sites in the U.S.
Milestone demonstrates CureVac’s and GSK’s continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseases

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK. The clinical trial is expected to provide valuable data to further evaluate the performance of CureVac’s second-generation mRNA backbone, which has the potential to be applied broadly in future vaccines against COVID-19 variants and other pathogens.

Please read the whole article here

CureVac AG, News 2022

March 24, 2022: Heidelberg Pharma AG

Heidelberg Pharma Announces Financial Figures for Fiscal Year 2021 and Provides Business Update

• Start of clinical trial with HDP-101 in multiple myeloma
• Signing of strategic partnership with Huadong Medicine
• Successful financing activities
• Financial figures in line with adjusted forecast
• Conference call to be held on 24 March 2022 at 3:00 p.m. CET

Heidelberg Pharma AG today published its financial results and Annual Report for fiscal year 2021 (1 December 2020 – 30 November 2021) and its outlook for 2022.

Please read the whole article here

Heidelberg Pharma AG, News 2022

March 23, 2022: Cosmo Pharmaceuticals NV

COSMO ANNOUNCES FULL-YEAR RESULTS 2021; CONFIRMS BEATING GUIDANCE

Cosmo Pharmaceuticals N.V. (“Cosmo”) reports full-year 2021 results for the year ended 31 December 2021, confirms beating guidance, and, as previously announced, proposes a dividend of €0.95 per share at the next AGM on 27 May 2022.

Please read the whole article here

Cosmo Pharmaceuticals NV, News 2022

March 23, 2022: Immatics Biotechnologies GmbH

Immatics Announces Full Year 2021 Financial Results and Corporate Update

IMA203 TCR-T candidate targeting PRAME demonstrated a 50% objective response rate across different solid tumor types in an interim update of Phase 1a dose escalation
Multiple IMA203 Phase 1b expansion cohorts being initiated in Q2 2022 including monotherapy at target dose level, checkpoint combination therapy, and 2nd-generation approach IMA203CD8
Immatics entered a global licensing agreement with Bristol Myers Squibb to collaborate on clinical development of TCR Bispecific (TCER®) IMA401 targeting MAGEA4/A8; agreement includes $150million upfront payment, up to $770 million in milestone payments, tiered double-digit royalties and a co-promotion option in the U.S.
TCER® IMA401 IND1 approved by regulatory authorities in February 2022; initiation of patient treatment in the first half of 2022
TCER® IMA402 targeting PRAME demonstrated preclinical proof-of-concept and initial steps towards GMP manufacturing have been initiated
Nancy Valente appointed to Immatics’ Board of Directors
Cash and cash equivalents as well as Other financial assets amount to $164 million2 (€145 million) as of December 31, 2021. Addition of upfront payment from the recent collaboration agreement with Bristol Myers Squibb received in February 2022 ensures cash runway into 2024

Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today provided an update on its corporate progress and reported financial results for the quarter and full year ended December 31, 2021.

Please read the whole article here

Immatics Biotechnologies GmbH, News 2022

March 22, 2022: AC Immune SA

AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update

Seven clinical data readouts expected in 2022

Three vaccines, targeting Tau, Abeta and alpha-synuclein, advancing in 2022

Semorinemab Phase 2 Lauriet trial: additional fluid biomarker data expected in H2 2022

Initiation of ACI-24 anti-Abeta vaccine Phase 1b/2 trial in patients with Alzheimer’s disease (AD) and people living with Down syndrome (DS) expected in H1 2022

AD/PD™ Conference: ACI-12589 identified as a reliable and accurate PET tracer for alpha-synucleinopathies (e.g. MSA)

Strong financial position of CHF 198.2 million ensures the Company is fully financed through at least Q1 2024

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported its financial results for the year ended December 31, 2021, and provided a corporate update, highlighting progress in its broad pipeline of products to treat and diagnose neurodegenerative diseases.

Please read the whole article here

AC Immune SA, News 2022

March 21, 2022: AC Immune SA

AC Immune to Host Key Opinion Leader Webinar on Alpha-Synuclein as a Target in Neurodegenerative Diseases

Webinar to take place on Tuesday, March 29th at 10:00 AM ET / 4:00 PM CET

AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, will host a key opinion leader (KOL) webinar on alpha-synuclein (a-syn) as a target in neurodegenerative diseases on March 29th at 10:00 AM ET / 4:00 PM CET.

Please read the whole article here

AC Immune SA, News 2022

March 18, 2022: Cosmo Pharmaceuticals NV

First U.S. trial using GI Genius™ intelligent endoscopy module shows 50% reduction in missed colorectal polyps with Artificial Intelligence (AI) technology versus standard colonoscopy

Cosmo Pharmaceuticals N.V. (“Cosmo”) announced that Medtronic on 16 March 2022 issued the following release:

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced final findings from a randomized, international, multi-center study that confirmed the effectiveness of the GI Genius™ intelligent endoscopy module, which uses AI as an aid in detecting colorectal polyps during colonoscopy, potentially helping to prevent colorectal cancer (CRC). The study, published on March 15 in Gastroenterology, the official medical journal of the American Gastroenterological Association, found that the use of GI Genius in conjunction with colonoscopy significantly decreases the miss rate (2x) of colorectal polyps and adenomas compared to standard colonoscopy.

Please read the whole article here

Cosmo Pharmaceuticals NV, News 2022

March 16, 2022: AC Immune SA

AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference

ACI-12589 distinguished multiple system atrophy (MSA) from other a-synucleinopathies and healthy volunteers

A-syn PET tracers may be developed to diagnose a-synuclein pathologies, including Parkinson’s disease, Lewy Body Dementia, MSA and others

AC Immune to host a-syn Key Opinion Leader webinar on March 29th

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the first non-invasive images of pathological alpha-synuclein (a-syn) in human brain and presented positive clinical proof-of-concept data for an a-syn positron emission tomography (PET) tracer as an imaging agent to identify MSA patients. The clinical trial of AC Immune’s wholly owned experimental a-syn PET tracer was conducted by the team of Oskar Hansson MD, PhD, at Lund University and Skåne University Hospital, with the support of a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).

Please read the whole article here

AC Immune SA, News 2022